Search Results - tianlei+ying

3 Results

Sort By:

Human Antibodies Against Middle East Respiratory Syndrome Coronavirus

Abstract: No effective therapeutics or vaccines against Middle East Respiratory Syndrome Coronavirus (MERS-CoV) are available. The human-to-human aspect of transmission and the high mortality rate associated with MERS-CoV infection have raised concerns over the potential for a future MERS-CoV pandemic and emphasized the need for development of effective...

Published: 5/22/2024 | Inventor(s): Dimiter Dimitrov, Tianlei Ying, Tina Ju, Kwok Yuen

Keywords(s): ANTIBODY, CORONAVIRUS, MERs, middle east respiratory syndrome

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Infectious Disease

Cancer Therapies Using Engineered Monomeric Fc Molecules

Abstract: The National Cancer Institute, Nanobiology Program seeks parties interested in collaborative research to co-develop engineered molecules therapies. Efforts to engineer antibody-based therapeutics, to date, have encountered technical limitations due to the relatively large fragment size and short fragment half-life. Antibody fragments are emerging...

Published: 5/22/2024 | Inventor(s): Dimiter Dimitrov, Tianlei Ying

Keywords(s): FcRn, IgG1, mabs, MFC, neonatal Fc receptor

Category(s): Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Therapeutics

Fusion Proteins as HIV-1 Entry Inhibitors

Abstract: Soluble forms of human CD4 (sCD4) inhibit HIV-1 entry into immune cells. Different forms of sCD4 and their fusion proteins have been extensively studied as promising HIV-1 inhibitors – including in animal models and clinical trials. However, they have not been successful in human studies due to their transient efficacy. sCD4 is also known...

Published: 5/22/2024 | Inventor(s): Dimiter Dimitrov, Weizhao Chen, Tianlei Ying

Keywords(s): antibody dependent cellular cytotoxicity (ADCC), Class II major histocompatibility complex (MHCII), Dimitrov, fusion protein, HIV-1, sCD4

Category(s): Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Infectious Disease